MedTrace Logo

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2021-02-18

No results posted yet for this study

Summary

Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.

Conditions

Interventions

DRUG

latanoprost 0.005%

placebo in the morning and latanoprost .005% in the evening

DRUG

fixed combination latanoprost-timolol

one drop in the morning and placebo in the evening

DRUG

timolol 0.5%

one drop in the morning and evening

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31
Primary Completion
1999-06-30
Completion
1999-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800267 on ClinicalTrials.gov